000 03371nam a22004455i 4500
001 978-1-59745-215-1
003 DE-He213
005 20161121230736.0
007 cr nn 008mamaa
008 100301s2007 xxu| s |||| 0|eng d
020 _a9781597452151
_9978-1-59745-215-1
024 7 _a10.1007/978-1-59745-215-1
_2doi
050 4 _aRC254-282
072 7 _aMJCL
_2bicssc
072 7 _aMED062000
_2bisacsh
082 0 4 _a616.994
_223
245 1 0 _aColorectal Cancer
_h[electronic resource] :
_bEvidence-Based Chemotherapy Strategies /
_cedited by Maurie Markman, Leonard B. Saltz.
264 1 _aTotowa, NJ :
_bHumana Press,
_c2007.
300 _bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
490 1 _aCurrent Clinical Oncology
505 0 _aMolecular Biology of Colon Cancer -- Chemoprevention of Colorectal Cancer -- Colorectal Cancer Screening and Surveillance -- Cytotoxic Chemotherapy for Metastatic Colorectal Cancer -- Integration of Antiangiogenic Strategies Into Colorectal Cancer Treatment -- The Role of EGFR Inhibition in Colorectal Cancer -- Second-Line Strategies in the Treatment of Patients With Metastatic Colorectal Cancer -- Adjuvant Chemotherapy for Colon Cancer -- Management of Locally Advanced Rectal Cancer -- Rationale for Adjuvant and Neoadjuvant Chemotherapy in the Resection of Liver Metastases -- Percutaneous Radiofrequency Ablation in the Management of Patients With Colorectal Cancer -- Colorectal Cancer Imaging -- Nursing Issues in Colorectal Cancer Chemotherapy -- Pain Management in the Colorectal Cancer Patient -- Novel Agents and New Paradigms for Colorectal Cancer Beyond EGFR and VEGF.
520 _aManagement options for patients with colorectal cancer have undergone d- matic changes over the past decade. Whereas at the start of 1996 only one drug, 5-Fluorouracil, was available for the treatment of this disease, a mere 10 yr later, six drugs are licensed for use in colorectal cancer, and others are in the late phases of clinical development. Likewise, surgical and ablative options, as well as an array of supportive medications, have shown substantial progress and undergone a dramatic proliferation over the past decade. With the increased number of therapeutic options from which to choose, the clinician is better able to offer effective therapy to the patient with colorectal cancer. The clinician is challenged, however, to keep up with the rapidly changing landscape and the rapidly emerging data that shape the options for treatment today and tom- row. In this text, leaders in the management of colorectal cancer review the current literature that has led us to where we are today. Critical evaluations of the data are offered, and evidence-based recommendations are made.
650 0 _aMedicine.
650 0 _aOncology.
650 1 4 _aMedicine & Public Health.
650 2 4 _aOncology.
700 1 _aMarkman, Maurie.
_eeditor.
700 1 _aSaltz, Leonard B.
_eeditor.
710 2 _aSpringerLink (Online service)
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9781588297518
830 0 _aCurrent Clinical Oncology
856 4 0 _uhttp://dx.doi.org/10.1007/978-1-59745-215-1
912 _aZDB-2-SME
950 _aMedicine (Springer-11650)
999 _c503304
_d503304